Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001558370-25-006010
Filing Date
2025-04-30
Accepted
2025-04-30 16:30:32
Documents
19
Period of Report
2025-06-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A plx-20250626xdef14a.htm   iXBRL DEF 14A 758124
2 GRAPHIC plx-20250626xdef14a_a003.jpg GRAPHIC 8004
3 GRAPHIC plx-20250626xdef14a_a004.jpg GRAPHIC 3343
4 GRAPHIC plx-20250626xdef14a_bg001.jpg GRAPHIC 106780
5 GRAPHIC plx-20250626xdef14a_bg002.jpg GRAPHIC 170278
  Complete submission text file 0001558370-25-006010.txt   3167740

Data Files

Seq Description Document Type Size
6 EX-101.SCH plx-20250626.xsd EX-101.SCH 3801
7 EX-101.LAB plx-20250626_lab.xml EX-101.LAB 3686
8 EX-101.PRE plx-20250626_pre.xml EX-101.PRE 3933
21 EXTRACTED XBRL INSTANCE DOCUMENT plx-20250626xdef14a_htm.xml XML 740014
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-33357 | Film No.: 25895942
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)